Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04419649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04419649 · ClinicalTrials.gov record · last posted 2026-08-21

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

StatusRecruiting
PhasePhase 2
SponsorTakeda
Started2020-08-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the study and learn about the effects of elritercept on anemia linked to MDS. The study will also look to learn how elritercept affects the production of healthy RBCs.

Protocol amendment history 1 change detected by DataLookout

2026-08-22
Trial sites expanded: 47 → 53 locations
Trial Details
NCT Number NCT04419649
Lead Sponsor Takeda
Conditions Myelodysplastic Syndromes, Cytopenia
Enrollment 160 participants
Start Date 2020-08-19
Primary Completion 2029-10-30 (estimated)
Study Completion 2031-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-21